Joseph Truitt - 09 Sep 2026 Form 4 Insider Report for Century Therapeutics, Inc. (IPSC)

Reporting relationship: Director
Issuer ticker: IPSC
Reported as of: 09 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Sep 2026, 17:48:53 UTC
Prior SEC filing: 20 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Douglas Carr, Attorney-in-Fact

Key filing fact

Joseph Truitt filed Form 4 for Century Therapeutics, Inc. (IPSC) on 10 Sep 2026.

Key facts

This page summarizes Joseph Truitt's Form 4 filing for Century Therapeutics, Inc. (IPSC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Sep 2026, 17:48.

Change

Previous filing in this sequence was filed on 20 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001452429 Primary reporting owner

Truitt Joseph

Relationship: Director
Address: C/O CENTURY THERAPEUTICS, INC., 25 N 38TH STREET, 12TH FLOOR, PHILADELPHIA
Signature: /s/ Douglas Carr, Attorney-in-Fact
Signature date: 10 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IPSC transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +148,000
Change %
Price: $0.000000^*
Shares after: 148,000
Date: 09 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 148,000
Exercise price: $2.03
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Century Therapeutics, Inc. (the "Company") issued to the Reporting Person stock options (the "Options") in connection with his appointment as a director. The Options vest in equal monthly installments over 36 months subject to the Reporting Person's continued service to the Company and are issued pursuant to the Company's 2021 Equity Incentive Plan.